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ABSTRACT
Objective: The objective of this research work to design nasal microspheres of ropinirole hydrochloride (HCL) using different mucoadhesive polymers 
by adopting the suitable technique. To study the influence of formulation and process variables on microsphere formation and release characteristics. 
To perform the physicochemical characterization of the prepared microspheres. To carry out in vitro drug release studies and to explore the release 
behavior using various kinetic models.
Methods: Experiments were performed with ropinirole HCL as a drug, chitosan, guar gum, carbopol 974P as a polymer. Span 80 and Tween 80 used 
light liquid paraffin, concentrated hydrochloric acid as solvent.
Result: The in vitro drug release studies were conducted for all the formulations, that is, F1-F21 in 250 ml phosphate buffer pH 6.6 for 12 hrs. Among 
them, F15 showed 82.7±0.23% drug release and F21 showed 81.2% in 12 hrs in a sustained manner.
Conclusion: Microspheres were formulated by emulsion solvent evaporation technique using different polymers. Apart from preventing nasal 
irritation, the microsphere possesses two major advantages over plain solutions, one is a high solubilization capacity for ropinirole HCL that exceeds 
their aqueous solubility and thus allows a reduction in the application volume. The results of this work indicate that intranasal microsphere of 
ropinirole may be beneficial for the treatment of Parkinson’s disease.
Keywords: Ropinirole hydrochloride, Parkinson’s disease, Microspheres.
INTRODUCTION
Microspheres are solid spherical particles ranging in size from 1 to 
1000 µm. They are spherical free flowing particles comprising proteins 
or synthetic polymers. The microspheres are free flowing powders 
including proteins or synthetic polymers, which are biodegradable 
in nature. There are two types of microspheres; microcapsules and 
micromatrices, which are described as microcapsules are those 
in which entrapped substance is distinctly surrounded by distinct 
capsule wall and micromatrices in which entrapped substance is 
dispersing throughout the microspheres matrix. Solid biodegradable 
microspheres incorporating a drug dispersed or dissolved through 
particle matrix have the potential for the controlled release of the drug. 
They are made up of polymeric, waxy, or other protective materials, 
that is, biodegradable synthetic polymers and modified natural 
products [1].
Delivery of drug into the brain for central nervous system (CNS) 
disease require treatment, however, such route of delivery is very 
problematic. Therapeutic effect of the drug can be described by 
achieving the desired concentration of drug in blood or tissue for a 
prolonged period. Hence, it is a reliable means to deliver a drug to a 
target site with specificity and in a controlled manner. Microsphere 
used as a not controlled release but for targeted therapy also so it 
offers certain advantages over the conventional release dosage form 
for those drugs having a first pass metabolism. All these drawbacks 
of conventional delivery system necessitate the development 
of controlled drug delivery system. Delivery of drug to CNS is 
problematic for drugs having a hydrophilic in nature and having a 
high molecular weight because of impervious nature of Blood-Brain 
Barriers (BBB) [2].
Parkinsonism disease is a leading cause of neurological disability and is 
the second most common progressive neurodegenerative disorder. The 
effect of the Parkinsonism disease reaches 1-2% in people over the age 
of 50. It has no gender preference and has a worldwide distribution. The 
symptoms of Parkinsonism disease are largely related to progressive 
loss of dopamine in the basal ganglia [3].
While enormous progress has been made regarding our 
understanding of the pathogenic mechanisms of neurological 
diseases, there are only a small number of effective drugs for treating 
this illness. A key obstacle for developing an effective treatment 
for neurological diseases is the blockage of drug entrance into the 
CNS by the BBB. <2% of all small molecule-drugs and virtually no 
large molecule drugs can cross the BBB. Therefore, it is of critical 
significance to search drug delivery strategies that can effectively 
deliver the drugs to CNS [4].
Recent developments in nasal drug delivery have suggested intranasal 
administration as a safe and acceptable route for brain targeting, 
especially for drugs with biological effects on the CNS and limited 
blood-brain permeability [5].
The nose to brain delivery would be beneficial in therapeutic 
situations where a rapid and/or specific targeting of drugs to the 
brain is required. Conditions such as Parkinson’s disease, Alzheimer’s 
disease or pain would be benefited from the development of nasal 
delivery systems, which will increase the fraction of drug that 
reaches the CNS after nasal delivery. The olfactory region located 
at the upper remote parts of the nasal passages offers the potential 
for certain compounds to circumvent the BBB and enter into the 
brain [6].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Intranasal delivery also offers the advantage of simple administration, 
cost effectiveness and convenient. This novel delivery method allows 
drugs, therapeutic proteins, polynucleotides, and viral vectors that 
do not normally cross the BBB to be delivered to the CNS. In addition, 
intranasal targeting of drugs to the CNS avoids first pass elimination 
by the liver allowing a lower therapeutic drug dose and fewer systemic 
side effects. Delivery from the nose to the CNS occurs within minutes 
along both the olfactory and trigeminal nerves. Delivery occurs by an 
extracellular route and does not require that the drugs bind to any 
receptor or undergo axonal transport [7-12].
Ropinirole, a recent introduction in the clinical treatment of Parkinson’s 
disease, suffers with the problems of low oral bioavailability and 
frequent dosing [13].
It is an orally administered non-ergoline dopamine agonist, and 
chemically it is hydrochloride (HCL) salt of 4-[2-(dipropyl amino) 
ethyl]-1, 3-dihydro-2H-indol-2-one with a molecular weight of 296.84. 
It is having short half-life (4-6 hrs) and low bioavailability (35%) due to 
extensive first pass metabolism [14].
The usual dose is 3-9 mg daily and has to be taken in three divided 
doses due to a short half-life of the drug [15].
Microspheres are solid spherical particles ranging from 1 to 1000 
µm. Bioadhesive microspheres give more residence time to facilitate 
absorption through nasal mucosa against nasal mucociliary 
clearance [1].
The treatment of all neurodegenerative diseases is a big challenge 
because of the numerous protective barriers surrounding the CNS. 
The targeting of drug to the CNS, for the therapeutic advancement of 
neurodegenerative disorders such as Alzheimer’s and Parkinson’s 
disease can be done by administering the drug formulation such as 
nanoparticle, liposome, microemulsion, and microsphere, which can 
cross the BBB or by delivering the drug formulation through intranasal 
route which can bypass the BBB [16].
Nasal delivery of drugs targeting the CNS is currently an area of great 
interest. In addition to “nose to brain delivery” intranasal drugs can 
enter through a “nose to systemic circulation to brain” pathway. In this 
case, it is necessary for the drug to readily permeate the BBB from the 
circulation. For this to be achieved the drug must exhibit satisfactory 




Experiments were performed with ropinirole HCL as a drug 
obtained from Hetero pharma, Hyderabad, India. Chitosan, guar gum, 
carbopol 974P as a polymer purchased from Finar chemicals limited, 
Ahmedabad and Burgoyne Burbridges and Co., Mumbai, India. Span 80 
and Tween 80 used as solvent purchased from Finar Chemicals Limited, 
Ahmedabad, India. Light liquid paraffin, concentrated hydrochloric acid 
obtained from Molychem, Mumbai, India.
Methods
Formulation of intranasal hydrogel microbeads of ropinirole HCL
Trial and error method
(Preliminary experiments) previously many trials were run for the 
preparation of microbeads of ropinirole HCL by emulsion solvent 
evaporation technique using different polymers. Trials were made by 
changing the temperature, stirring speeds, the concentration of the 
polymer, Tween-80, Span-80. After so many trials, it was concluded that 
temperature play a very critical role in the formation of microbeads, it 
is a continuous process of stirring, with the combination of hydrophilic 
and lipophilic surfactants. Every step in the process was optimized by 
performing experiments through trial and error method.
Preparation of ropinirole HCL microspheres
Ropinirole HCL microspheress are prepared by emulsion solvent 
evaporation technique using three polymers, that is, chitosan, carbopol 
974P and guar gum individually and in combinations. The following 
are the steps for the preparation of microbeads. Polymer (chitosan, 
carbopol 974P and guar gum) was allowed to hydrate in 40ml of 
water for some time to achieve a viscous solution. Weighed quantity of 
ropinirole HCL was dispersed in 10 ml of water and this was added to 
the polymer dispersion. To the above drug-gum dispersion 0.1% Tween 
80 was added under constant stirring. Separately 200 ml of light liquid 
paraffin was measured in a glass beaker and to this 0.1% Span 80 was 
added to it. The oil phase was placed on a hot plate fitted with a remi 
stirrer, and aqueous phase/polymer dispersion was added to the oil 
phase in a thin stream over 2-3 minutes. This emulsion was stirred at 
2000 rpm and heated to 80°C for 3-4 hrs. The aqueous phase evaporates 
leaving the microspheres dispersed in the oil phase. Microspheres were 
harvested by decantation from the oil phase and washed 3-4 times 
with 100 ml aliquots of n-Hexane to make the Microbeads free from 
oil. Then, these are allowed to dry at 40°C for 1 hr in a hot air oven. 
All the microbeads were stored in tight containers till taken for further 
evaluation (Table 1).
RESULTS AND DISCUSSION
A total of 21 formulations of ropinirole HCL microspheres with 
various polymers were formulated individually and in combination 
by an emulsion solvent evaporation technique. The formulations 
were subjected to evaluation parameters such as particle size, surface 
morphology, drug entrapment efficiency (DEE), Swelling studies, 
in-vitro mucoadhesive studies, and in-vitro drug release studies.
Standard calibration curve of ropinirole HCL
Preparation of standard stock solution:
 100 mg of ropinirole HCL was accurately weighed and dissolve 
into 100 ml volumetric flask containing pH 6.6 buffer solution 
to get a concentration of (1000 µg/ml), that is, stock solution-I. 
from this 1 ml was withdrawn and diluted to 100 ml with pH 6.6 
phosphate buffer, to get a concentration of (10 µg/ml), that is, 
stock solution-II.
Calibration curve of pH 6.6 phosphate buffer solution
From the stock solution-II, 2,4,6,8, and 10 ml sample were withdrawn 
and volume was made up to the mark with pH 6.6 phosphate buffer. 
This solution gives 2, 4, 6, 8, and 10 µg/ml concentration of ropinirole 
HCL. The absorbance of these solutions measured in UV at 250 nm 
using pH 6.6 phosphate buffer as blank. Standard calibration curve of 
ropinirole HCL in 6.6 pH phosphate buffer solution at λ max 250 nm 
(Table 2 and Fig. 1).
Characterization of ropinirole HCL microspheres
Micromeritic properties of microspheres
All the formulations F1-F21 are evaluated for bulk density, 
tapped density, Carr’s compressibility index, and Hausner’s ratio. 
Compressibility, that is, Carr’s index, was found to be between 5.17% 
and 22.8% and Hausner’s ratio was found to be between 1.05 and 1.29, 
all the parameters indicating good flow property (Table 3).
Percentage yield
Percentage yield of different formulations, F1-F21, were calculated 
and the yield was found to be in the range of 86-98.9%, respectively. 
This higher percentage yield indicates that this emulsion solvent 
evaporation method was very useful for adoption in the formulation of 
ropinirole HCL microspheres.
Particle size analysis
Particle size distribution of ropinirole HCL microspheres was 
determined by optical microscope fitted with an ocular micrometer 
and stage micrometer. All the formulations of micro beads F1-F21 show 
uniform size distribution. The average particle size of ropinirole HCL 
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microspheres was found to be in the range of 280±3.15-535±2.28 µm. As 
the polymer concentration was increased, the size of the microspheres 
was also found to be increased.
Drug entrapment efficiency (DEE)
The entrapment process was found to be good and in the range of 
61.1±2.5-94.4±1.38% for the formulations F1-F15 and 83.4±2.43-
95.3±2.81% for the formulations F16-F21. The percentage of 
entrapment was higher, 94.4±1.38% for F5 (5% chitosan), 92.3±1.91% 
for F10 (3.5% carbopol 974P) and 93.7±1.28% for F15 (3.5% guar 
gum) formulation. This improved entrapment efficiency is simply due 
to the greater proportion of polymers with respect to the amount of 
drug.
Loose surface crystallography (LSC)
LSC studies were conducted for all the drug-loaded formulations F1-
F15 and F16-F21. Surface-associated drug content of microspheres 
decreased with increase in the concentration of the polymer. As the 
polymer concentration increased from F1-F5, F6-F10 and F11-F15 
it showed increased entrapment efficiencies and hence decreased 
surface drug contents. However in formulations with low polymer 
concentration the surface associated drug content was more in 
F1 (30.22%), F6 (32.13%) and F11 (25.01%) formulations due to the 
lower entrapment efficiency. The surface associated drug content for 
combination formulations, F16-F21 ranged between 10% and 18.8% 
(Table 4 and Figs. 2-5).
Swelling index (SI)
Swelling property was mostly affected by the concentration of polymer. 
As the concentration of polymers, that is, chitosan, carbopol 974P and 
guar gum increases the swelling capacity increased. The SI for all the 
formulations, that is, F1-F21 was determined in pH 6.6 phosphate 
buffer. The SI increased from F1 (175.3±8.07%) to F5 (55.2±12.6%), 
F6 (169.2±8.3%) to F10 (311.4±11.25%), F11 (159.8±9.13%) to 
F15 (330.5±11.1%) in pH 6.6 buffer at the end of 2 hrs. The increase in 
the SI is due to the increase in the polymer concentration. The swelling 
capacity in pH 6.6 phosphate buffer is more which indicated the greater 
swelling capacity in alkaline medium. The SI of F16-F21 formulations 
ranged from 270±8.34% to 350±9.6% in the pH6.6 buffer at the end of 
2 hrs. This is due to the higher concentration of combination polymers 
due to the combinations of polymers (Table 5).
In vitro drug release studies
The in vitro drug release studies were conducted for all the 
formulations, that is, F1-F21 in 250 ml phosphate buffer pH 6.6 for 
Table 1: Formulation of ropinirole HCL microspheres




Tween 80% Span 80% Liquid 
paraffin (ml)
F1 50 1 - - 0.1 0.1 200
F2 50 1.5 - - 0.1 0.1 200
F3 50 2.5 - - 0.1 0.1 200
F4 50 3.5 - - 0.1 0.1 200
F5 50 5 - - 0.1 0.1 200
F6 50 - 1 - 0.1 0.1 200
F7 50 - 1.5 - 0.1 0.1 200
F8 50 - 2 - 0.1 0.1 200
F9 50 - 2.5 - 0.1 0.1 200
F10 50 - 3.5 - 0.1 0.1 200
F11 50 - - 1 0.1 0.1 200
F12 50 - - 1.5 0.1 0.1 200
F13 50 - - 2 0.1 0.1 200
F14 50 - - 2.5 0.1 0.1 200
F15 50 - - 3.5 0.1 0.1 200
F16 50 1.75 - 1.75 0.1 0.1 200
F17 50 2.5 - 2.5 0.1 0.1 200
F18 50 1.75 1.75 - 0.1 0.1 200
F19 50 2.5 2.5 - 0.1 0.1 200
F20 50 - 1.75 1.75 0.1 0.1 200
F21 50 - 2.5 2.5 0.1 0.1 200
HCL: Hydrochloride









Fig. 1: Standard graph
Fig. 2: Comparison of results of particle size analysis between F1 
and F15 formulations
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drug release in 12 hrs showing sustained release due to increase 
in polymer concentration, that is, 5% chitosan. Similarly, for the 
formulations F6-F10 the drug release was found to be in the range of 
85.8±0.43-96.8±0.55% and F10 showing 85.8±0.43% drug release as 
sustained manner in 12 hrs when compared to the other formulations. 
This is due to increase in the polymer concentration, that is, up to 3.5% 
carbopol 974P. Similarly, for the formulations F11-F15, the percentage 
drug release was found to be in the range of 82.7±0.23-95.5±0.83% 
and F15 showing 82.7±0.23% drug release as the sustained manner 
in 12 hrs as compared to the other formulations. Hence, this is due 
to increase in the polymer concentration up to 3.5% Guar gum. The 
comparative dissolution studies were conducted for the formulations 
F5, F10, and F15. Among them, F15 showed 82.7±0.23% drug release 
in 12 hrs in a sustained manner. Hence, the formulation F15 is suitable 
for sustained release of ropinirole HCL and also showed the better 
percentage yield, encapsulation efficiency, and swelling properties. The 
in vitro drug release for the formulations F16 and F17 are 87.5% and 
82.9%, respectively in 12 hrs. This showed sustained release due to the 
combination of chitosan and guar gum in polymer concentrations LL 
Table 3: Results of the micrometric properties of formulations F1‑F21
Formulation code Bulk density (g/cc3) Tapped density (g/cc3) Compressibility index (%) Hausners ratio
F1 0.26±0.012 0.31±0.023 16.1±1.33 1.19±0.03
F2 0.28±0.083 0.38±0.032 21.3±0.63 1.25±0.02
F3 0.41±0.033 0.47±0.010 12.76±1.34 1.14±0.13
F4 0.29±0.032 0.35±0.009 17.14±1.38 1.2±0.03
F5 0.5±0.062 0.55±0.033 9.09±1.22 1.1±0.02
F6 0.33±0.092 0.41±0.023 19.51±1.68 1.24±0.03
F7 0.28±0.083 0.38±0.032 21.3±0.63 1.25±0.02
F8 0.27±0.071 0.35±0.044 22.8±1.72 1.29±0.05
F9 0.27±0.040 0.35±0.009 22.8±1.77 1.29±0.10
F10 0.62±0.033 0.71±0.034 12.6±0.72 1.14±0.04
F11 0.26±0.012 0.31±0.023 16.1±1.33 1.19±0.03
F12 0.41±0.033 0.47±0.010 12.76±1.34 1.14±0.13
F13 0.45±0.062 0.5±0.052 10±0.56 1.11±0.12
F14 0.5±0.062 0.55±0.033 9.09±1.22 1.1±0.02
F15 0.29±0.042 0.35±0.023 17.14±1.63 1.2±0.18
F16 0.45±0.023 0.5±0.023 10±1.33 1.11±0.02
F17 0.35±0.043 0.41±0.033 14.6±1.54 1.17±0.11
F18 0.62±0.062 0.66±0.013 6.06±1.99 1.06±0.13
F19 0.55±0.033 0.58±0.013 5.17±0.77 1.05±0.16
F20 0.17±0.064 0.29±0.024 21.3±1.45 1.25±0.03
F21 0.28±0.083 0.38±0.032 21.3±0.63 1.25±0.02
Each sample was analyzed in triplicate (n=3±SD), SD: Standard deviation
Table 4: Data of evaluation parameters of MS microbeads formulations F1‑F21
Formulation code Yield (%) Particle size (µm) Drug entrapment efficiency (%) LSC (%)
F1 88.3 300±3.12 65±1.03 30.22±0.16
F2 91.8 355±3.68 77±2.22 22.14±0.15
F3 98.1 440±2.96 84±2.4 19.32±0.18
F4 98.3 495±3.76 87.5±3.32 15.12±0.11
F5 95.8 525±2.82 94.4±1.38 10.1±0.17
F6 89 325±4.58 61.1±2.5 32.13±0.22
F7 95.4 390±4.23 77.6±2.17 23.13±0.15
F8 96 430±2.83 83±3.33 18.09±0.16
F9 98.3 466±3.66 89.2±2.35 12.2±0.18
F10 96.6 495±2.76 92.3±1.91 10.3±0.16
F11 94.2 280±3.15 75.7±1.33 25.01±0.17
F12 96.5 324±2.83 81.2±2.42 19.21±0.11
F13 93.1 465±4.28 88.9±2.01 15.24±0.18
F14 96.5 488±3.68 91.2±3.12 12±0.23
F15 96 535±2.28 93.7±1.28 10.8±0.10
F16 98.9 390±2.82 84.1±1.29 18.3±0.14
F17 92.2 495±3.23 93.8±1.99 10.0±0.18
F18 89.3 415±3.33 83.4±2.43 18.8±0.14
F19 94 470±2.82 95.1±3.31 9.48±0.19
F20 95.2 410±2.35 85.4±1.35 17.8±0.18
F21 86 512±3.66 95.3±2.81 9.22±0.11
Each sample was analyzed in triplicate (n=3±SD), SD: Standard deviation
Fig. 3: Comparison of results of particle size analysis between F16 
and F21 formulations
12 hrs. The percentage of drug release for formulations F1-F5 were 
found to be in the range of 86.4±1.22-98.9±0.54% the maximum drug 
release was found to be 98.9±0.54% in formulation F1 in 12 hrs due 
to the initial burst release but the formulation F5 showed 86.4±1.22% 
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(3.5%) and HH (5%), respectively. The drug release for the formulations 
F18 and F19 in 16 hrs are 89.1% and 83.6%, respectively. This showed 
drug release in a sustained manner due to the combination of polymers 
chitosan and carbopol 974P in concentrations LL (3.5%) and HH (5%), 
respectively. The drug release for the formulations F20 and F21 in 
16 hrs are 85.6% and 81.2%, respectively. The sustained release in 
these formulations are due to the combination of polymers carbopol 
974P and guar gum in concentrations LL (3.5%) and HH (5%). The 
comparative dissolution was run for the formulations F17. F19, F21. 
Among them, F21 showed 81.2% drug release in 12 hrs in a sustained 
manner. Hence, the formulation F21 is also suitable for sustained 
release of ropinirole HCL using a combination of polymers, guar gum 
(Table 6-11 and Figs. 6-11).
Drug release kinetics
The in vitro dissolution data for formulations F1-F21 were analyzed for 
different kinetic models to find out which drug release mechanism it 
follows. The values of correlation (r) were calculated and were found 
to be more linear for first-order release as compared to zero order. The 
kinetic data were best-fitted to Higuchi model and good regression 
coefficients were observed.
The kinetic model graphs of F15 formulation and F21 were found best 
formulation (Table 12 and Figs. 12-21).
Scanning electron microscopy (SEM)
Surface morphology and internal cross-sectional structure of the 
microspheres were investigated with SEM. SEM photomicrographs of 
Fig. 4: Comparison of results of surface associated drug content 
between F1 and F15 formulations
Fig. 5: Comparison of results of surface associated drug content 
between F16 and F21 formulations
Fig. 6: Graph showing cumulative % drug release of formulations 
F1‑F5
Table 6: Dissolution profile at pH 6.6 phosphate buffer for 
ropinirole HCL loaded chitosan microspheres
Time (hrs) F1 F2 F3 F4 F5
0 0 0 0 0 0
1 33.5 29.2 26.5 23.4 21
2 37.6 35.7 33.4 25.7 24.4
4 52 46.2 39 36.4 33.9
6 67.1 60.4 52.9 47.3 41.4
8 82 78.3 68.6 60.2 56.1
12 98.9 95.5 91.3 89 86.4
HCL: Hydrochloride
Table 5: Data of swelling index of formulations, F1‑F21






















Each sample was analyzed in triplicate (n=3±SD), SD: Standard deviation
Table 7: Dissolution profile at pH 6.6 phosphate buffer for 
ropinirole HCL loaded carbopol 974P microspheres
Time (hrs) F6 F7 F8 F9 F10
0 0 0 0 0 0
1 25.5 22.5 21.2 21.3 18
2 35.8 30 28.4 24.6 22.5
4 42.7 37.8 35.1 32.5 25.6
6 74.6 63.5 61.5 46.9 35.6
8 77.9 70.1 66.2 59.2 53.2
12 96.8 94.3 91.1 88.1 85.8
HCL: Hydrochloride
Table 8: Dissolution profile at pH 6.6 phosphate buffer for 
ropinirole HCL loaded Guar gum microspheres
Time (hrs) F11 F12 F13 F14 F15
0 0 0 0 0 0
1 48 36.7 24 21.07 20.4
2 54.7 40.6 34.3 29.4 27.6
4 59.5 53.5 49.9 39.1 34
6 65.9 61.7 55.3 46.6 43.3
8 75.8 70 63.2 54.1 50.8
12 95.5 92.8 90.1 87.5 82.7
HCL: Hydrochloride
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the optimized formulation are shown in Fig. 22. The microspheres were 
smooth, spherical, and discrete particles. Very less particulate matter 
of the drug were seen on the surface of the microspheres indicating 
uniform distribution of the drug in the polymer network.
Fig. 7: Graph showing cumulative % drug release of formulations 
F6‑F10
Fig. 8: Graph showing cumulative % drug release of formulations 
F11‑F15
Fig. 9: Comparison of cumulative % drug release of formulations 
F5, F10 and F15
Fig. 10: Graph showing cumulative % drug release of 
formulations F16‑F21
Fig. 11: Comparison of % cumulative drug release of optimized 
polymer concentration formulations F17, F19 and F21
Fig. 12: Zero order release for F15 formulation
Table 9: Dissolution profile at pH 6.6 phosphate buffer for 
ropinirole HCL loaded optimized formulations
Time (hrs) F5 F10 F15
0 0 0 0
1 21 18 20.4
2 24.4 22.5 27.6
4 33.9 25.6 34
6 41.4 35.6 43.3
8 56.1 53.2 50.8
12 86.4 85.8 82.7
HCL: Hydrochloride
Table 10: Dissolution profile at pH 6.6 phosphate 
buffer for ropinirole HCL loaded chitosan ‑ Guar gum, 
chitosan ‑ carbopol974P and carbopol974P ‑ Guar Gum 
microspheres
Time (hrs) F16 F17 F18 F19 F20 F21
0 0 0 0 0 0 0
1 17.7 12.9 22.2 18.9 14.4 18.9
2 26.1 26.7 28.2 22.2 23.7 22.8
4 44.2 42.4 38.5 34 42.7 34.6
6 49 47.8 46.9 41.2 50.8 40.6
8 57.2 52.8 59.2 54.2 54.7 50.9
12 87.5 82.9 89.1 83.6 85.6 81.2
HCL: Hydrochloride
Stability studies
At the end of stability studies, the microspheres were checked for any 
changes in physical stability, size, shape, drug content and release 
profile. Selected formulations like F15 & F21 microsphere were 
subjected to exhaustive stability testing at 25±2°C 60±5% RH for 
1st and 2nd month and 40±2°C 75±5% RH for 3rd months. Samples were 
withdrawn at 1, 2 and 3 months period according to ICH guidelines. 
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Fig. 13: First order release for F15 formulation
Fig. 14: Higuchi model for F15 formulation
Fig. 15: Korsemeyer peppas model for F15 formulation
Fig. 16: Hixon crowell model for F15 formulation
Fig. 18: First order release for 21 formulation
Fig. 19: Higuchi model for F21 formulation
Fig. 20: Korsemeyer Peppas model for F21 formulation
Fig. 17: Zero order release for 21 formulation
The both formulations (F15 and F21) did not show any changes in 
physical stability, size, shape, drug content and release profile at 
intermediate conditions. A stability study has been observed in 
Tables 13 and 14.
CONCLUSION
Microspheres were formulated by emulsion solvent evaporation 
technique using different polymers. Trials were made by changing 
Table 11: Dissolution profile at pH 6.6 phosphate buffer for 
ropinirole HCL optimized combination formulations
Time (hrs) F17 F19 F21
0 0 0 0 
1 12.9 18.9 18.9
2 26.7 22.2 22.8
4 42.4 34 34.6
6 47.8 41.2 40.6
8 52.8 54.2 50.9
12 82.9 83.6 81.2
HCL: Hydrochloride
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Table 12: In vitro drug release kinetics studies (regression coefficient [r2]) of prepared ropinirole HCL microspheres
Formulation code Zero (r2) First (r2) Higuchi (r2) Korsmeyer Peppas (r2) Hixon Crowell (r2)
F1 0.861 0.967 0.983 0.971 0.991
F2 0.883 0.988 0.984 0.974 0.982
F3 0.915 0.983 0.986 0.963 0.985
F4 0.95 0.976 0.985 0.962 0.99
F5 0.96 0.957 0.976 0.962 0.979
F6 0.855 0.98 0.966 0.955 0.973
F7 0.909 0.973 0.981 0.969 0.985
F8 0.912 0.979 0.978 0.964 0.98
F9 0.957 0.974 0.98 0.096 0.989
F10 0.972 0.947 0.944 0.922 0.972
F11 0.739 0.962 0.922 0.947 0.935
F12 0.839 0.977 0.979 0.978 0.967
F13 0.894 0.983 0.996 0.995 0.98
F14 0.94 0.942 0.987 0.988 0.968
F15 0.944 0.949 0.98 0.976 0.967
F16 0.935 0.978 0.993 0.992 0.986
F17 0.922 0.972 0.986 0.965 0.973
F18 0.948 0.968 0.99 0.984 0.986
F19 0.964 0.981 0.981 0.976 0.991
F20 0.93 0.972 0.988 0.984 0.978
F21 0.958 0.97 0.983 0.98 0.982
Each sample was analyzed in triplicate (n=3±SD), SD: Standard deviation, HCL: Hydrochloride
Table 13: Stability studies of formulation F15 as per ICH Guidelines
Characteristics Initials 30 days 60 days 90 days
25±2°C 60±5% RH 25±2°C 60±5%RH 25±2°C 60±5% RH 40±2°C 75±5% RH
Drug entrapment efficiency (%) 93.7±1.28 93.4±0.32 92.9±1.05 92.5±0.92
Swelling index (%) in pH 6.6 buffer 330.5±11.1 325±8.2 320±8.0 315±6.6
In vitro drug release (%) 82.7±0.23 83.4±0.32 83.97±0.71 84.02±0.36
HCL: Hydrochloride
Table 14: Stability studies of formulation F21 as per ICH guidelines
Characteristics Initials 30 days 60 days 90 days
25±2°C 60±5% RH 25±2°C 60±5%RH 25±2°C 60±5% RH 40±2°C 75±5% RH
Drug entrapment efficiency (%) 95.3±2.81 4.3±0.05 4.3±0.05 4.3±0.05
Swelling index (%) in pH 6.8 buffer 350±9.6 345±6.3 345±8.4 342±4.51
In vitro drug release (%) 81.2±0.45 81.89±0.33 82.97±0.47 83.02±0.16
HCL that exceeds their aqueous solubility and thus allows a reduction 
in the application volume. The other advantage is that the drug can 
be rapidly absorbed after nasal administration of the microsphere 
to meet the emergency treatment purpose. These results indicate 
that intranasal microsphere of ropinirole may be beneficial for the 
treatment of Parkinson’s disease.
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Fig. 21: Hixon crowell model for F21 formulation
the temperature, stirring speeds, concentration of the polymer, 
Tween-80, Span-80. After so many trials, it was concluded that 
temperature play a very critical role in the formation of microbeads, 
it is a continuous process of stirring, with the combination of 
hydrophilic and lipophilic surfactants. Apart from preventing nasal 
irritation, the microsphere possesses two major advantages over 
plain solutions, one is a high solubilization capacity for ropinirole 
Fig. 22: Scanning electron micrograph of F15 formulation 
(a) group of microspheres and (b) single microsphere
a b
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